<!DOCTYPE html>
<html>
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" name="viewport"/>
<link href="../../../webpages.css" rel="stylesheet"/>
</head>
<body>
<div class="banner">
<div class="banner-content">
<h1>DermpathNet</h1>
</div>
</div>
<nav>
<a href="../../../index.html" target="_blank">
<text type="button">Home</text>
</a>
<a href="../../../browser-page-317.html" target="_blank">
<text type="button">Browse</text>
</a>
<a href="../../../download-page.html" target="_blank">
<text type="button">Downloads</text>
</a>
<a href="../../../contact-us.html" target="_blank">
<text type="button">About</text>
</a>
</nav>
<footer class="site-footer">
<p>@2024 New York University Grossman School of Medicine, Weill Cornell Medicine</p>
<!--<p>Privacy Policy | Terms of Service | Cookie Policy</p>-->
</footer>
<title>Tumoral melanosis associated with combined BRAF/MEK inhibition (dabrafenib/trametinib) in metastatic melanoma.-DermPath</title>
<div class="content-container"> <div class="figures-container"> <div class="image-side"> <img alt="Tumoral melanosis associated with combined BRAF/MEK inhibition (dabrafenib/trametinib) in metastatic melanoma." class="clickable-image" src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180233/bin/gr2.jpg"/> </div> <div class="text-side"> <h1>Tumoral melanosis associated with combined BRAF/MEK inhibition (dabrafenib/trametinib) in metastatic melanoma.</h1> <p>A, Large nodular collection of heavily pigmented melanophages in the dermis. No viable melanoma cells were identified. B, Immunohistochemistry shows strong positive staining for CD68 and C, negative staining for S100. (A, Hematoxylin-eosin stain; C, red chromagen; original magnifications: A, x20; B and C, x100.)</p> <p>PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/30320196/" target="_blank">30320196</a></p><p>Type: Premalignant/Malignant, Category: Melanocytic</p>
</div> </div></div></body></html>